Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
At present, introduction of target therapy to chronic myelogenous leukemia (CML) treatment made CML not life-limiting disorder. The main condition of treatment efficacy is its continuity. The most common causes of dose reduction and CML therapy interruption is hematologic toxicities such as neutrope...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/12 |
| _version_ | 1826557211713732608 |
|---|---|
| author | V. A. Shuvaev M. S. Fominykh I. S. Martynkevich V. Y. Udaleva N. A. Potikhonova M. N. Zenina K. M. Abdulkadyrov |
| author_facet | V. A. Shuvaev M. S. Fominykh I. S. Martynkevich V. Y. Udaleva N. A. Potikhonova M. N. Zenina K. M. Abdulkadyrov |
| author_sort | V. A. Shuvaev |
| collection | DOAJ |
| description | At present, introduction of target therapy to chronic myelogenous leukemia (CML) treatment made CML not life-limiting disorder. The main condition of treatment efficacy is its continuity. The most common causes of dose reduction and CML therapy interruption is hematologic toxicities such as neutropenia and thrombocytopenia. The adverse events correction in these circumstances is vital. Recommendations for neutropenia and thrombocytopenia correction are proposed in this article. The basement and results of the use of granulocyte colony stimulating factor (G-CSF) and thrombopoietine receptor agonist for hematologic toxicities correction with clinical case are presented. |
| first_indexed | 2024-04-09T20:25:25Z |
| format | Article |
| id | doaj.art-6386b1fc13004cc0a3c2a849d453ad09 |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2025-03-14T08:25:00Z |
| publishDate | 2014-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-6386b1fc13004cc0a3c2a849d453ad092025-03-02T13:07:08ZrusABV-pressОнкогематология1818-83462413-40232014-07-018471210.17650/1818-8346-2013-8-4-7-1227Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patientsV. A. Shuvaev0M. S. Fominykh1I. S. Martynkevich2V. Y. Udaleva3N. A. Potikhonova4M. N. Zenina5K. M. Abdulkadyrov6Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyAt present, introduction of target therapy to chronic myelogenous leukemia (CML) treatment made CML not life-limiting disorder. The main condition of treatment efficacy is its continuity. The most common causes of dose reduction and CML therapy interruption is hematologic toxicities such as neutropenia and thrombocytopenia. The adverse events correction in these circumstances is vital. Recommendations for neutropenia and thrombocytopenia correction are proposed in this article. The basement and results of the use of granulocyte colony stimulating factor (G-CSF) and thrombopoietine receptor agonist for hematologic toxicities correction with clinical case are presented.https://oncohematology.abvpress.ru/ongm/article/view/12chronic myelogenous leukemiatyrosine kinase inhibitorsimatinibdasatinibthrombocythopenianeutropeniaromiplostim |
| spellingShingle | V. A. Shuvaev M. S. Fominykh I. S. Martynkevich V. Y. Udaleva N. A. Potikhonova M. N. Zenina K. M. Abdulkadyrov Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients Онкогематология chronic myelogenous leukemia tyrosine kinase inhibitors imatinib dasatinib thrombocythopenia neutropenia romiplostim |
| title | Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients |
| title_full | Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients |
| title_fullStr | Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients |
| title_full_unstemmed | Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients |
| title_short | Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients |
| title_sort | tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in cml patients |
| topic | chronic myelogenous leukemia tyrosine kinase inhibitors imatinib dasatinib thrombocythopenia neutropenia romiplostim |
| url | https://oncohematology.abvpress.ru/ongm/article/view/12 |
| work_keys_str_mv | AT vashuvaev tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients AT msfominykh tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients AT ismartynkevich tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients AT vyudaleva tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients AT napotikhonova tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients AT mnzenina tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients AT kmabdulkadyrov tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients |